Clinical Trial Update: Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating oral hydroxychloroquine for retinitis pigmentosa caused by the P23H-RHO rhodopsin mutation has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• Hydroxychloroquine (hydroxychloroquine)

Snippet

Sponsor: University of Michigan | Conditions: Retinitis Pigmentosa | Phase 1, Phase 2 | Status: TERMINATED